Canakinumab in Patients With COVID-19 and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.

Also called NCT04510493

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 116 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04510493
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04510493. Randomized; double masking; primary purpose treatment. Start 2020-10-23 (actual); primary completion 2021-08-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
Acronym
CanCovDia
Condition
Coronavirus Infection
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Canakinumab
Intervention (Drug)
Placebo
Lead sponsor
University Hospital, Basel, Switzerland (class: other)
Collaborator
Novartis (class: industry)
Collaborator
Swiss National Science Foundation (class: other)

Record details

Record id
cardio:ct-nct04510493
Content hash
fac51ff4a7f7e2d5d995488e488e7c7b83ac24898302353a5a78dcaa72c823b0